TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Admission for ulcer bleeding or haemorrhagic gastritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Easiness score of IUD insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Weight for Length (WLZ) Z Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight for Age (WAZ) Z Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Length for Age (LAZ) Z Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dynamic Visual Analogue Scale (DVAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complete or partial disease remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve beginning from the first dose until the last quantifiable concentration of telotristat ethyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PTA (pure tone audiogram) in the affected ear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PHQ9 Depression Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of selected oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: blastocystis development rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of Responders According to the Modified Teacher's Drooling Scale (mTDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DRM Memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Object Memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Efficacy of Botulinum Toxin A in reducing hyperhidrosis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic Progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of overall glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Macrophage Activation, TNF-a
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Macrophage Activation, GM-CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interleukin, IL-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Measurement of regulatory T cells (CD4+CD25+FoxP3+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline for Visual Analog Scale - Cold Water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline for Dentin Sensitivity Cold Water as Assessed by the Schiff Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline for 5 Face Emoticon Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composite Endpoint of Venous Thromboembolism and VTE-related Death
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in CRP Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Marginal ulcer rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improved prenatal mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: insight variation between hospitalization periods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cocontraction Index (CCI) between the rectus femoris and the semitendinosus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Psoriasis Area and Severity Index (PASI) 75
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator's Global Assessment (IGA) Mod 2011 0/1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SARS-CoV-2 infection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative Consumption of Opioids Total Daily Morphine Equivalent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of household members infected by SARS-CoV-2
Endpoint domain: Mortality/survival
Primary endpoint: duration of primary COVID-19 symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of late-onset cardiovascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: frequency of postviral fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: frequency of noticeable temporary hair loss after COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in Safety Lab parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in vital signs
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in 12-lead electrocardiograms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Ocular Dose Limiting Events (DLEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Drug Related Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Level of Quality of life: EQ-5D
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: degree of independence in activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: level of burden
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Disease Activity Score (DAS28-CRP) change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of dose limited toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum measured concentration of the biomarker level in plasma (Emax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic Images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QT intervals corrected for heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Medical Interview Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: De novo diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma Lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity and specificity of SN histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Person-time Incidence Rates (Subject Based)
Endpoint domain: Adverse events/effects
Primary endpoint: Person-time Incidence Rates (Event Based)
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor Response by EASL Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumor Response by RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Recurrent ischemic CVA or TIA
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in the severity of GERD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adverse events (AEs) related to treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline Numeric Pain Rating Scale at one week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Mechanical allodynia at one week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Wind-Up at one week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Upper limb neurodynamic test at one week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Muscle endurance (flexor digiturum profundis and superficialis) test at one week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with at least one Hypoglycemia event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in MYMOP2 score from baseline to 4 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in MYMOP2 score from baseline to 16 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in MYMOP2 score from 4 months to 16 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: transplant survival
Endpoint domain: Mortality/survival
Primary endpoint: Bioavailability of Drug (F) for Oral Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Plasma Clearance (CL) for IV Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) for Oral Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung Volume Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Fat Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SCORAD Score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T Regulatory cell activity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: prevalence of psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: cancer worry
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: prevalence of psychological morbidity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Average Total Body Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax (Time at Which Cmax First Observed)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MGH Skin Picking Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Skin Picking Impact Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Skin Picking Treatment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excess BMI Loss percentage (EBL%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in the rate of ATP recovery (Vmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of life measurement using EQ-5D
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Median Progression-free Survival (PFS) Rate at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Change from Baseline Participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in the Degree of Tricuspid Regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: The Mean Gradient Across the Tricuspid Valve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the Degree of TV Leaflet Coaptation Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the Degree of TV Leaflet Tethering Height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Smoking Cessation Rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Activity level of patients with Parkinson Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of TpCO2 and PaCO2 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time in shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time in respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Symptoms-diagnose time interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scheltens scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elbow Range of Motion (ROM) at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Relative systemic bioavailability (Frel)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Physical Dimensions in Health Status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cerebral hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Usability of the FloRite™ system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean probing pocket depth (PPD) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve from Time 0 to Last Observable Concentration (AUCT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of abnormal partial thromboplastin time values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fowler dead space
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Degree of concordance (Kappa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Ethanol Withdrawal Score (SEWS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of visualization of local anesthetic injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualitative detection of Chlamydia trachomatis and/or Neisseria gonorrhoeae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Frequency of evaluation of target organs preclinical impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial Blush Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of highly proliferative clones isolated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance of OSNA Breast Cancer System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of intraoperative frozen section protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in T2 Mapping for cartilage lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual Beta-cell Function (RBCF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Days with fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Children Safety Knowledge and Skills
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Teachers' Knowledge/Attitudes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rate of exacerbations of COPD (AECOPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Downstream flow patterns (helicity and vorticity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hinge washout
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune signaling events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum safe dose of sunitinib
Endpoint domain: Adverse events/effects
Primary endpoint: Hand function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinical Response Within 48 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Response Within 7 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiological Response Within 48 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Microbiological Response Within 7 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mixed oxygen saturation in central venous blood (ScvO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary electrolytes (sodium, potassium, chloride)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best response (complete and partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of subjects experiencing ≥50% reduction in average daily pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASES Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-reported urinary continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area under the concentration-time curve of BI 1356 in plasma (AUC0-72)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum measured concentration (Cmax) of BI 1356 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibromyalgia Impact Questionnaire (FIQR)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: World Health Organization Quality of Life - BREF (WHOQOL-BREF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: recurrence of ocular inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in rate of glucose disappearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: overall longitudinal myocardial strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change rate of Jankovic Rating Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of gingival pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Delay in detection of cough effort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall incidence of treatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's Yale-Brown Obsessive Compulsive Scale Modified for Autism Spectrum Disorder (CY-BOCS-ASD) - Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful transvaginal removal of gallbladder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of patients free of asthmatic crisis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Interferon-y production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interleukin-2 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine profile analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time UP and Go
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Barthel Activity of Daily Living Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Centre for epidemiological Studies Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Diagnostic accuracy in primary medullary thyroid cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy in recurrent medullary thyroid cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Mature Oocytes Retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Participants With Ovarian Hyper Stimulation Syndrome (OHSS)
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic rate of early gastric cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants With Treatment-related Adverse Events (AEs) Leading to Both Study Drugs Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Antibody Titers Against HPV-16 and HPV-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of voids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of leakages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: compliance of empiric antibiotic treatment within first hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eradication of overall MRSA carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: VAS of intensity of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean Heart Rate Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes